Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster Vaccination

NCT06167915 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV-2
COVID-19 Vaccine

Interventions

BIOLOGICAL: 30μg dose of LYB002V14
BIOLOGICAL: 60μg dose of LYB002V14
BIOLOGICAL: placebo

Sponsor

Guangzhou Patronus Biotech Co., Ltd.

Collaborators

[object Object]